PMID- 17459550
OWN - NLM
STAT- MEDLINE
DCOM- 20070828
LR  - 20221207
IS  - 0278-5846 (Print)
IS  - 0278-5846 (Linking)
VI  - 31
IP  - 5
DP  - 2007 Jun 30
TI  - Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor 
      in depressed patients.
PG  - 1034-7
AB  - Brain-derived neurotrophic factor (BDNF) is an important member of the 
      neurotrophin family of growth factors, abundant in the brain and periphery. 
      Researchers have reported that serum BDNF levels in drug-free depressed patients 
      are lower than those of healthy controls, and have proposed that these low levels 
      might reflect a failure of neuronal plasticity in depression. In the present 
      study, we investigated the effects of paroxetine, an SSRI, and milnacipran, an 
      SNRI, on serum BDNF levels in depressed patients. Serum levels of BDNF were 
      measured by ELISA before, 4 weeks, and 8 weeks after the start of treatment with 
      antidepressants. Forty-two patients were randomly administered paroxetine (21 
      cases) or milnacipran (21 cases). A negative correlation was found between serum 
      BDNF levels and baseline Ham-D scores. The response and remission rates for each 
      drug were not significantly different. Serum BDNF levels in responders were 
      significantly increased 2.6- and 1.8-fold 8 weeks after treatment with paroxetine 
      or milnacipran, respectively. These results suggest that both drugs improve the 
      depressive state by increasing BDNF levels.
FAU - Yoshimura, Reiji
AU  - Yoshimura R
AD  - Department of Psychiatry, University of Occupational and Environmental Health, 
      1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, Fukuoka, Japan. 
      yoshi621@med.uoeh-u.ac.jp
FAU - Mitoma, Masae
AU  - Mitoma M
FAU - Sugita, Atsuko
AU  - Sugita A
FAU - Hori, Hikaru
AU  - Hori H
FAU - Okamoto, Tatsuya
AU  - Okamoto T
FAU - Umene, Wakako
AU  - Umene W
FAU - Ueda, Nobuhisa
AU  - Ueda N
FAU - Nakamura, Jun
AU  - Nakamura J
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20070307
PL  - England
TA  - Prog Neuropsychopharmacol Biol Psychiatry
JT  - Progress in neuro-psychopharmacology & biological psychiatry
JID - 8211617
RN  - 0 (Adrenergic Uptake Inhibitors)
RN  - 0 (Antidepressive Agents, Second-Generation)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Cyclopropanes)
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - 41VRH5220H (Paroxetine)
RN  - G56VK1HF36 (Milnacipran)
SB  - IM
MH  - Adrenergic Uptake Inhibitors/adverse effects/*therapeutic use
MH  - Adult
MH  - Aged
MH  - Antidepressive Agents, Second-Generation/adverse effects/*therapeutic use
MH  - Brain-Derived Neurotrophic Factor/*blood
MH  - Cyclopropanes/adverse effects/*therapeutic use
MH  - Depressive Disorder/*blood/*drug therapy/psychology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Milnacipran
MH  - Paroxetine/adverse effects/*therapeutic use
MH  - Psychiatric Status Rating Scales
MH  - Selective Serotonin Reuptake Inhibitors/adverse effects/*therapeutic use
EDAT- 2007/04/27 09:00
MHDA- 2007/08/29 09:00
CRDT- 2007/04/27 09:00
PHST- 2006/11/21 00:00 [received]
PHST- 2007/01/21 00:00 [revised]
PHST- 2007/03/01 00:00 [accepted]
PHST- 2007/04/27 09:00 [pubmed]
PHST- 2007/08/29 09:00 [medline]
PHST- 2007/04/27 09:00 [entrez]
AID - S0278-5846(07)00095-4 [pii]
AID - 10.1016/j.pnpbp.2007.03.001 [doi]
PST - ppublish
SO  - Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jun 30;31(5):1034-7. doi: 
      10.1016/j.pnpbp.2007.03.001. Epub 2007 Mar 7.